Printer Friendly
The Free Library
19,607,050 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

FDA Requests Additional Information on VelaSmooth 510K Submission.


YOKNEAM, Israel -- Syneron Medical Ltd. (Nasdaq:ELOS), an innovator in the development, marketing and sales of ELOS(TM) combined-energy medical aesthetic devices, today announced that the U.S. Food and Drug Administration (FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
) has requested additional technical information on its 510(k) Premarket Notification application for the VelaSmooth(TM) system.

Head of Clinical and Regulatory Affairs Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy, and banking. Regulatory Affairs professionals usually have responsibility for the following general areas:
 for Syneron, Dr. Amir Waldman, reported that "The FDA asked two specific technical questions and we promptly submitted answers to these inquiries according to according to
prep.
1. As stated or indicated by; on the authority of: according to historians.

2. In keeping with: according to instructions.

3.
 standard 510(k) procedure."

About Syneron

Syneron Medical Ltd. (Nasdaq:ELOS) manufactures and distributes medical aesthetic devices that are powered by the proprietary, patented ELOS combined-energy technology of Bi-Polar Radio Frequency and Light. The Company's innovative ELOS technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite cel·lu·lite
n.
A fatty deposit causing a dimpled or uneven appearance, as around the thighs.


Cellulite
Cellulite is dimply skin caused by uneven fat deposits beneath the surface.
. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. is located in Israel. Syneron has offices and distributors throughout the world, including North American North American

named after North America.


North American blastomycosis
see North American blastomycosis.

North American cattle tick
see boophilusannulatus.
 Headquarters in Canada, European Headquarters in Germany, and Asia-Pacific Headquarters in Hong Kong Hong Kong (hŏng kŏng), Mandarin Xianggang, special administrative region of China, formerly a British crown colony (2005 est. pop. 6,899,000), land area 422 sq mi (1,092 sq km), adjacent to Guangdong prov. , which provide sales, service and support. Additional information can be found at www.syneron.com.

For more information, please contact Moshe Mizrahy, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of Syneron Medical Ltd., at +972 4 909-6349, email: moshem@syneron.com, Dr. Amir Waldman, VP Clinical and Regulatory Affairs at +972 4 909-6352, email: amirw@syneron.com
Syneron Medical Ltd.
Soltam Technology Park
P.O.B. 550
Yokneam Illit, 20692
Israel
Tel: +972 4 909-6200
Fax: +972 4 909-6202
info@syneron-med.com


Syneron, the Syneron logo, ELOS, Comet, and VelaSmooth are trademarks of Syneron Medical Ltd. and may be registered in certain jurisdictions. ELOS (Electro-Optical Synergy) is a proprietary technology of Syneron Medical. All other names are the property of their respective owners.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1CANA
Date:May 20, 2005
Words:329
Previous Article:QXSystems Announces Launch of WorkACE to Enable Global Enterprises to Build True Virtual Working Communities to Take Advantage of Their Knowledge...
Next Article:Aegis Industries Sponsors Stun Gun Special Session at Bioelectromagentic Society Meetings, Dublin, Ireland, June 19.
Topics:



Related Articles
Enhancing efficiency: step by step.
Breast implants, Hippocrates, and burden of proof.
Cell Robotics International corrects date of 510K submission; should read November 1996 sted 1997.
FDA eyes pharmacogenomics data.
FDA Requests Resubmission of Syneron Medical's VelaSmooth Device under PMA Guidelines.
Syneron Sets Guidance for 2005 at $75M, a 30% Increase Over 2004; Guidance for 2004 Raised to $58M.
Regulatory acceptance of toxicogenomics data.
Workgroup report: review of genomics data based on experience with mock submissions--view of the CDER pharmacology toxicology Nonclinical...

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles